Base de dados : LILACS
Pesquisa : C04.557.470.035 [Categoria DeCS]
Referências encontradas : 787 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 79 ir para página                         

  1 / 787 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Moreira, Ayrton Custódio
Czepielewski, Mauro A
Texto completo
Id: lil-785230
Autor: Machado, Márcio Carlos; Fragoso, Maria Candida Barisson Vilares; Moreira, Ayrton Custódio; Boguszewski, César Luiz; Vieira Neto, Leonardo; Naves, Luciana A; Vilar, Lucio; Araújo, Luiz Antônio de; Czepielewski, Mauro A; Gadelha, Monica R; Musolino, Nina Rosa Castro; Miranda, Paulo Augusto C; Bronstein, Marcello Delano; Ribeiro-Oliveira Jr, Antônio.
Título: Recommendations of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism for the diagnosis of Cushing's disease in Brazil
Fonte: Arch. endocrinol. metab. (Online);60(3):267-286tab, graf.
Idioma: en.
Resumo: ABSTRACT Although it is a rare condition, the accurate diagnosis and treatment of Cushing’s disease is important due to its higher morbidity and mortality compared to the general population, which is attributed to cardiovascular diseases, diabetes mellitus and infections. Screening for hypercortisolism is recommended for patients who present multiple and progressive clinical signs and symptoms, especially those who are considered to be more specific to Cushing’s syndrome, abnormal findings relative to age (e.g., spinal osteoporosis and high blood pressure in young patients), weight gain associated with reduced growth rate in the pediatric population and for those with adrenal incidentalomas. Routine screening is not recommended for other groups of patients, such as those with obesity or diabetes mellitus. Magnetic resonance imaging (MRI) of the pituitary, the corticotropin-releasing hormone (CRH) test and the high-dose dexamethasone suppression test are the main tests for the differential diagnosis of ACTH-dependent Cushing’s syndrome. Bilateral and simultaneous petrosal sinus sampling is the gold standard method and is performed when the triad of initial tests is inconclusive, doubtful or conflicting. The aim of this article is to provide information on the early detection and establishment of a proper diagnosis of Cushing’s disease, recommending follow-up of these patients at experienced referral centers. Arch Endocrinol Metab. 2016;60(3):267-86.
Descritores: Adenoma/diagnóstico
Síndrome de Cushing/diagnóstico
Consenso
Adenoma Hipofisário Secretor de ACT/diagnóstico
-Brasil
Dexametasona
Hidrocortisona/sangue
Imagem por Ressonância Magnética
Adenoma/complicações
Cromatografia Líquida de Alta Pressão
Síndrome de Cushing/etiologia
Diagnóstico Diferencial
Adenoma Hipofisário Secretor de ACT/complicações
Glucocorticoides
Limites: Humanos
Responsável: BR1.1 - BIREME


  2 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Boguszewski, Cesar L
Texto completo
Id: lil-792938
Autor: Vieira Neto, Leonardo; Boguszewski, Cesar L; Araújo, Luiz Antônio de; Bronstein, Marcello D; Miranda, Paulo Augusto C; Musolino, Nina R de C; Naves, Luciana A; Vilar, Lucio; Ribeiro-Oliveira Júnior, Antônio; Gadelha, Mônica R.
Título: A review on the diagnosis and treatment of patients with clinically nonfunctioning pituitary adenoma by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism
Fonte: Arch. endocrinol. metab. (Online);60(4):374-390, Aug. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Clinically nonfunctioning pituitary adenomas (NFPA) are the most common pituitary tumors after prolactinomas. The absence of clinical symptoms of hormonal hypersecretion can contribute to the late diagnosis of the disease. Thus, the majority of patients seek medical attention for signs and symptoms resulting from mass effect, such as neuro-ophthalmologic symptoms and hypopituitarism. Other presentations include pituitary apoplexy or an incidental finding on imaging studies. Mass effect and hypopituitarism impose high morbidity and mortality. However, early diagnosis and effective treatment minimizes morbidity and mortality. In this publication, the goal of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism is to provide a review of the diagnosis and treatment of patients with NFPA, emphasizing that the treatment should be performed in reference centers. This review is based on data published in the literature and the authors’ experience. Arch Endocrinol Metab. 2016;60(4):374-90.
Descritores:
Neoplasias Hipofisárias/diagnóstico
Neoplasias Hipofisárias/terapia
Neuroendocrinologia
Adenoma/diagnóstico
-Sociedades Médicas
Brasil
Imagem por Ressonância Magnética
Adenoma/terapia
Fatores de Risco
Diagnóstico Precoce
Antineoplásicos/uso terapêutico
Limites: Humanos
Masculino
Feminino
Tipo de Publ: Revisão
Responsável: BR1.1 - BIREME


  3 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-827783
Autor: Cakir, Bekir; Polat, Sefika Burcak; Kilic, Mehmet; Ozdemir, Didem; Aydin, Cevdet; Süngü, Nuran; Ersoy, Reyhan.
Título: Evaluation of preoperative ultrasonographic and biochemical features of patients with aggressive parathyroid disease: is there a reliable predictive marker?
Fonte: Arch. endocrinol. metab. (Online);60(6):537-544, Nov.-Dec. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective Parathyroid cancer (PC) represents < 1% of cases of PHPT. Tumors demonstrating atypical histopathologic features and don’t fulfill criteria for carcinoma are classified as atypical adenomas (APA). The purpose of this study was to determine a biochemical or ultrasonographic feature that can predict aggressive disease requiring more extensive surgery and closer follow-up. Subjects and methods Twenty eight patients operated for PHPT and diagnosed with atypical adenoma (23 patients) or carcinoma (5 patients) were enrolled in this study. The control group consisted of 102 patients operated between the same dates and diagnosed with classical PA. Classical adenomas, atypical adenomas, and carcinomas were compared according to their biochemical and ultrasonographic parameters. Results Serum Ca levels were significantly higher in the PC group compared with the APA and classical PA groups. Serum median PTH, Serum ALP and UCa was significantly higher in the APA and carcinoma groups compared to the classical PA group. ROC analysis was made to determine the best cut off values for predicting aggressive disease were 12.45 mg/dL, 265.05 pg/mL, 154.5 IU/l, 348.5 mg/day and 21.5 mm for Ca, PTH, ALP, UCa and the adenoma diameter, respectively. Multivariate analysis showed that serum Ca, ALP and isoechoic/cystic appearance were independent predictors for aggressive disease. Conclusion Preoperatively high PTH, ALP, and UCa levels and large lesions with isoechoic or cystic appearances may be predictive of atypical adenoma or carcinoma in patients being evaluated for PHPT. In such cases, surgeons may prefer en bloc parathyroidectomy to minimally invasive surgery.
Descritores: Neoplasias das Paratireoides/sangue
Neoplasias das Paratireoides/diagnóstico por imagem
Biomarcadores Tumorais/sangue
Adenoma/cirurgia
Adenoma/patologia
Adenoma/sangue
Adenoma/diagnóstico por imagem
-Hormônio Paratireóideo/sangue
Neoplasias das Paratireoides/cirurgia
Neoplasias das Paratireoides/patologia
Cuidados Pré-Operatórios
Estudos de Casos e Controles
Cálcio/urina
Cálcio/sangue
Valor Preditivo dos Testes
Ultrassonografia/métodos
Fosfatase Alcalina/sangue
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME


  4 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-827797
Autor: Day, Patricia Fainstein; Loto, Monica Graciela; Glerean, Mariela; Picasso, María Fabiana Russo; Lovazzano, Soledad; Giunta, Diego Hernán.
Título: Incidence and prevalence of clinically relevant pituitary adenomas: retrospective cohort study in a Health Management Organization in Buenos Aires, Argentina
Fonte: Arch. endocrinol. metab. (Online);60(6):554-561, Nov.-Dec. 2016. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives The main purpose of this study was to estimate the incidence rate and prevalence of clinically relevant pituitary adenomas (PAs) within the Hospital Italiano Medical Care Program (HIMCP), a well-defined population of 150,000 members living in the urban and suburban area of the city of Buenos Aires. We defined clinically relevant PAs as those associated with endocrine dysfunction and/or mass effect. Subjects and methods A retrospective open cohort study was conducted, including all members of the HIMCP over 18 years old, with active memberships during the period of the study, from January 1st 2003, to January 1, 2014. The incidence rates (IRs) were standardized (SIR) to the World Health Organization (WHO) 2000 standard population and were expressed per 100,000 members/year. Prevalence was estimated at January 1, 2014, and was expressed per 100,000 persons. The clinical records have been electronically managed since 2001. All lab and imaging studies were done in-house. Results The overall SIR was 7.39/100,000/year (95% CI 4.47-10.31). Female patients had a specific IR significantly higher than male patients (5.85 vs.1.54) and represented 73% of the affected members. Regarding tumor size, 61.4% were microadenomas, and the mean age at diagnosis was 46.4 years. Prolactinomas had the highest SIR (5.41), followed by acromegaly (Acro) and non-functioning adenomas (NFAs) with overlapping 95% CIs (0.44-1.41 and 0.31-0.99, respectively). Microprolactinomas were more frequent in female (72.6%) (p < 0.01) and younger members (38 vs.60 years; p < 0.04). The overall prevalence rate was 97.76/100,000. Prolactinomas had the highest prevalence (56.29), followed by NFAs (21.48), Acro (14.07) and CD (5.93). Conclusion Our results demonstrate that clinically relevant PAs are more common than usually suspected, especially prolactinomas and growth-hormone secreting PAs. These data highlight the need to increase the awareness of PAs, thereby enabling early diagnosis and treatment.
Descritores: Neoplasias Hipofisárias/epidemiologia
Prolactinoma/epidemiologia
Adenoma/epidemiologia
Adenoma Hipofisário Secretor de Hormônio do Crescimento/epidemiologia
-Argentina/epidemiologia
Incidência
Prevalência
Estudos Retrospectivos
Distribuição por Sexo
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Adulto Jovem
Responsável: BR1.1 - BIREME


  5 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-887587
Autor: Rosario, Pedro Weslley; Calsolari, Maria Regina.
Título: Long-term follow-up of patients with elevated IGF-1 and nadir GH > 0 4 µg/L but < 1 µg/L
Fonte: Arch. endocrinol. metab. (Online);61(5):426-431, Sept.-Oct. 2017. tab.
Idioma: en.
Resumo: ABSTRACT Objective To report the results of initial investigation and after 5 years of patients with a suspicious clinical scenario for acromegaly, elevated IGF-1, and nadir GH during an oral glucose tolerance test (OGTT) > 0.4 µg/L but < 1 µg/L. Subjects and methods Seventeen patients who had elevated IGF-1 (outside puberty and pregnancy) in two measurements and GH between 0.4 and 1 µg/L during OGTT were selected. Results During initial assessment, only one patient had microadenoma on magnetic resonance imaging (MRI) of the pituitary. In this patient, IGF-1 returned to normal spontaneously after 5 years. In the remaining 16 patients, spontaneous normalization of IGF-1 was observed in four and IGF-1 continued to be elevated in 12 after 5 years. None of the latter patients developed a phenotype of acromegaly, changes in physiognomy or increase in IGF-1 and no tumor was detected by imaging methods. Two patients had nadir GH < 0.4 µg/L, while the nadir GH remained between 0.4 and 1 µg/L in 10 patients. Conclusion In patients (notably young adult or adult women) without a typical phenotype in whom IGF-1 is measured due to a suspicious clinical scenario and is found to be slightly elevated, even if confirmed and in the absence of other causes, a nadir GH cut-off value of 0.4 µg/L instead of 1 µg/L in the OGTT might be inadequate for the diagnosis.
Descritores: Neoplasias Hipofisárias/sangue
Acromegalia/sangue
Fator de Crescimento Insulin-Like I/análise
Adenoma/sangue
Hormônio do Crescimento Humano/sangue
-Fenótipo
Neoplasias Hipofisárias/diagnóstico por imagem
Fatores de Tempo
Imagem por Ressonância Magnética
Biomarcadores/sangue
Adenoma/diagnóstico por imagem
Seguimentos
Teste de Tolerância a Glucose
Limites: Humanos
Masculino
Feminino
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Adulto Jovem
Responsável: BR1.1 - BIREME


  6 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1001215
Autor: Li, Yi-Lin; Zhang, Shuo; Guo, Xiao-Peng; Gao, Lu; Lian, Wei; Yao, Yong; Deng, Kan; Wang, Ren-Zhi; Xing, Bing.
Título: Correlation analysis between short-term insulin-like growth factor-I and glucose intolerance status after transsphenoidal adenomectomy in acromegalic patients: a large retrospective study from a single center in China
Fonte: Arch. endocrinol. metab. (Online);63(2):157-166, Mar.-Apr. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objectives: Our study aimed to investigate the associations of glucose tolerance status with insulin-like growth factor-I (IGF-I) and other clinical laboratory parameters of acromegalic patients before and after the patients underwent transsphenoidal adenomectomy (TSA) by conducting a single-center, retrospective study. Subjects and methods: A total of 218 patients with acromegaly who had undergone TSA as the first treatment were retrospectively analyzed. Serum IGF-I, growth hormone (GH) and glucose levels were measured before and after surgery. Results: The follow-up levels for random GH, GH nadir, and the percentage of the upper limit of normal IGF-I (%ULN IGF-I) were decreased significantly. The percentages of normal (39.0%), early carbohydrate metabolism disorders (33.0%) and diabetes mellitus (28.0%) changed to 70.2%, 16.5% and 13.3%, respectively, after TSA. %ULN IGF-I at baseline was higher in the diabetes mellitus (DM) group than in the normal glucose tolerance group and impaired glucose tolerance (IGT) /impaired fasting glucose (IFG) groups before TSA, and the DM group exhibited a greater reduction in %ULN IGF-I value after surgery. The follow-up %ULN IGF-I value after surgery was significantly lower in the improved group, and Pearson's correlation analysis revealed that the reductions in %ULN IGF-I corresponded with the reductions in glucose level. Conclusion: This study examined the largest reported sample with complete preoperative and follow-up data. The results suggest that the age- and sex-adjusted IGF-I level, which reflects altered glucose metabolism, and the change of it are associated with improved glucose tolerance in acromegalic patients both before and after TSA.
Descritores: Acromegalia/sangue
Fator de Crescimento Insulin-Like I/análise
Adenoma/cirurgia
Intolerância à Glucose/sangue
Adenoma Hipofisário Secretor de Hormônio do Crescimento/cirurgia
-Período Pós-Operatório
Glicemia/análise
Adenoma/sangue
Estudos Retrospectivos
Seguimentos
Resultado do Tratamento
Hormônio do Crescimento Humano/sangue
Diabetes Mellitus/sangue
Adenoma Hipofisário Secretor de Hormônio do Crescimento/sangue
Período Pré-Operatório
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  7 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1011171
Autor: Santana, Nathalie Oliveira; Freitas, Ricardo Miguel Costa; Marcos, Vinicius Neves; Chammas, Maria Cristina; Camargo, Rosalinda Yossie Asato; Schmerling, Cláudia Kliemann; Vanderlei, Felipe Augusto Brasileiro; Hoff, Ana Oliveira; Marui, Suemi; Danilovic, Debora Lucia Seguro.
Título: Diagnostic performance of thyroid ultrasound in Hürthle cell carcinomas
Fonte: Arch. endocrinol. metab. (Online);63(3):300-305, May-June 2019. tab, graf.
Idioma: en.
Projeto: Fundação de Amparo à Pesquisa do Estado de São Paulo.
Resumo: ABSTRACT Objective Hürthle cell carcinomas (HCCs) of the thyroid have been recently reclassified as a separate entity due to their distinct clinical and molecular profiles. Few studies have assessed the ability of preoperative characteristics in differentiating HCCs from Hürthle cell adenomas (HCAs) due to the low prevalence of both lesions. This study aimed to compare the preoperative features of HCCs and HCAs and evaluate the diagnostic performance of ultrasound in distinguishing between both. Subjetcs and methods Retrospective study including 101 patients (52 HCCs and 49 HCAs) who underwent thyroid surgery from 2000 to 2016. Clinical, ultrasonographic, and histological data were reviewed. Diagnostic performance of suspicious sonographic features was analyzed in 51 cases (24 HCCs and 27 HCAs). Results Hürthle cell neoplasms were predominant in females. Subjects ≥ 55 years represented 58% of the cases of HCCs and 53% of those of HCAs. Carcinomas were significantly larger (p < 0.001), and a tumor size ≥ 4 cm significantly increased the risk of malignancy (odds ratio 3.67). Other clinical, cytologic, and sonographic data were similar between HCCs and HCAs. Among the HCCs, the lesions were purely solid in 54.2%, hypoechoic in 37.5%, and had coarse calcifications in 12.5%, microcalcifications in 8.3%, irregular contours in 4.2%, and a taller-than-wide shape in 16.7%. Predominantly/exclusive intranodular vascularization was observed in 52.6%. Overall, 58% of the HCCs were classified as TI-RADS 4 or 5 compared with 48% of the HCAs. TI-RADS 4 or 5 had a specificity of only 51.8% and a positive likelihood ratio of 1.21. Conclusions Apart from the lesion size, no other preoperative feature adequately distinguished HCCs from HCAs. Sonographic characteristics raising suspicion for malignancy, which are mostly present in papillary carcinomas, were infrequent in HCCs. New tools must be developed to improve preoperative diagnosis and deferral of surgery in cases of adenomas.
Descritores: Glândula Tireoide/diagnóstico por imagem
Neoplasias da Glândula Tireoide/diagnóstico por imagem
Adenoma/diagnóstico por imagem
Carcinoma Papilar, Variante Folicular/diagnóstico por imagem
Ultrassonografia Doppler/métodos
-Glândula Tireoide/cirurgia
Glândula Tireoide/patologia
Neoplasias da Glândula Tireoide/cirurgia
Neoplasias da Glândula Tireoide/patologia
Adenoma/cirurgia
Adenoma/patologia
Estudos Retrospectivos
Carcinoma Papilar, Variante Folicular/cirurgia
Carcinoma Papilar, Variante Folicular/patologia
Diagnóstico Diferencial
Limites: Humanos
Masculino
Feminino
Adulto
Pessoa de Meia-Idade
Idoso
Responsável: BR1.1 - BIREME


  8 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Boguszewski, Cesar L
Czepielewski, Mauro Antônio
Texto completo
Id: biblio-1019350
Autor: Boguszewski, Cesar L; Huayllas, Martha Katherine P; Vilar, Lucio; Naves, Luciana Ansaneli; Ribeiro-Oliveira Junior, Antonio; Soares, Beatriz Santana; Czepielewski, Mauro Antonio; Abucham, Julio; Correa-Silva, Silvia Regina; Bronstein, Marcello Delano; Jallad, Raquel Soares; Duarte, Felipe Gaia; Musolino, Nina Rosa; Kasuki, Leandro; Gadelha, Monica Roberto.
Título: Brazilian multicenter study on pegvisomant treatment in acromegaly
Fonte: Arch. endocrinol. metab. (Online);63(4):328-336, July-Aug. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were included. Efficacy was defined as any normal IGF-I measurement during treatment. Safety data were reviewed. Predictors of response were determined by comparing controlled versus uncontrolled patients. Results 109 patients [61 women; median age at diagnosis 34 years; 95.3% macroadenomas] from 10 Brazilian centers were studied. Previous treatment included surgery (89%), radiotherapy (34%), somatostatin receptor ligands (99%), and cabergoline (67%). Before PEGV, median levels of GH, IGF-I and IGF-I % of upper limit of normal were 4.3 µg/L, 613 ng/mL, and 209%, respectively. Pre-diabetes/diabetes was present in 48.6% and tumor remnant in 71% of patients. Initial dose was 10 mg/day in all except 4 cases, maximum dose was 30 mg/day, and median exposure time was 30.5 months. PEGV was used as monotherapy in 11% of cases. Normal IGF-I levels was obtained in 74.1% of patients. Glycemic control improved in 56.6% of patients with pre-diabetes/diabetes. Exposure time, pre-treatment GH and IGF-I levels were predictors of response. Tumor enlargement occurred in 6.5% and elevation of liver enzymes in 9.2%. PEGV was discontinued in 6 patients and 3 deaths unrelated to the drug were reported. Conclusions In a real-life scenario, PEGV is a highly effective and safe treatment for acromegaly patients not controlled with other therapies.
Descritores: Acromegalia/tratamento farmacológico
Receptores de Somatostatina/uso terapêutico
Hormônio do Crescimento Humano/análogos & derivados
Cabergolina/uso terapêutico
-Glicemia/análise
Brasil
Fator de Crescimento Insulin-Like I/análise
Hormônio do Crescimento/sangue
Adenoma/tratamento farmacológico
Valor Preditivo dos Testes
Resultado do Tratamento
Quimioterapia Combinada
Cabergolina/administração & dosagem
Limites: Humanos
Masculino
Feminino
Criança
Adolescente
Adulto
Pessoa de Meia-Idade
Idoso
Idoso de 80 Anos ou mais
Adulto Jovem
Tipo de Publ: Estudo Multicêntrico
Responsável: BR1.1 - BIREME


  9 / 787 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: biblio-1019354
Autor: García, William Rojas; Cortes, Henry Tovar; Romero, Andrés Florez.
Título: Pituitary gigantism: a case series from Hospital de San José (Bogotá, Colombia)
Fonte: Arch. endocrinol. metab. (Online);63(4):385-393, July-Aug. 2019. tab, graf.
Idioma: en.
Resumo: ABSTRACT Introduction Gigantism is a rare pediatric disease characterized by increased production of growth hormone (GH) before epiphyseal closure, that manifests clinically as tall stature, musculoskeletal abnormalities, and multiple comorbidities. Materials and methods Case series of 6 male patients with gigantism evaluated at the Endocrinology Service of Hospital de San José (Bogotá, Colombia) between 2010 and 2016. Results All patients had macroadenomas and their mean final height was 2.01 m. The mean age at diagnosis was 16 years, and the most common symptoms were headache (66%) and hyperhidrosis (66%). All patients had acral changes, and one had visual impairment secondary to compression of the optic chiasm. All patients underwent surgery, and 5 (83%) required additional therapy for biochemical control, including radiotherapy (n = 4, 66%), somatostatin analogues (n = 5, 83%), cabergoline (n = 3, 50%), and pegvisomant (n = 2, 33%). Three patients (50%) achieved complete biochemical control, while 2 patients showed IGF-1 normalization with pegvisomant. Two patients were genetically related and presented a mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene (pathogenic variant, c.504G>A in exon 4, p.Trp168*), fulfilling the diagnostic criteria of familial isolated pituitary adenoma. Conclusions This is the largest case series of patients with gigantism described to date in Colombia. Transsphenoidal surgery was the first-choice procedure, but additional pharmacological therapy was usually required. Mutations in the AIP gene should be considered in familial cases of GH-producing adenomas.
Descritores: Neoplasias Hipofisárias/terapia
Adenoma/terapia
Gigantismo/terapia
-Linhagem
Neoplasias Hipofisárias/diagnóstico
Fator de Crescimento Insulin-Like I/análise
Hormônio do Crescimento/sangue
Adenoma/diagnóstico
Estudos Retrospectivos
Seguimentos
Resultado do Tratamento
Distribuição por Sexo
Colômbia
Peptídeos e Proteínas de Sinalização Intracelular/genética
Adenoma Hipofisário Secretor de Hormônio do Crescimento/genética
Gigantismo/diagnóstico
Mutação/genética
Limites: Humanos
Masculino
Adolescente
Adulto Jovem
Responsável: BR1.1 - BIREME


  10 / 787 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-981247
Autor: Yoncón Romero, Ricardo; Portilla Yépez, William.
Título: Adenoma de tiroides de células bizarras, a propósito de un caso / Thyroid adenoma of bizarre cells: with regard to a case
Fonte: Cambios rev. méd;16(2):81-84, jul.- 2017. ilus, graf.
Idioma: es.
Resumo: Introducción: El adenoma folicular de núcleos bizarros es un tipo de adenoma folicular de tiroides, con apariencia histológicamente preocupante pero de curso clínico benigno. Caso: Presentamos una paciente con antecedentes de hipertiroidismo en tratamiento con tiamazol. Debido a la presencia de un nódulo tiroideo se le practicó punción con aguja fina de la glándula. El estudio histopatológico demostró la presencia de células de Hürthle e identificó células características de adenoma folicular de núcleos bizarros. En el Ecuador no se reportó ningún caso similar. Discusión: Las células que tienen mutaciones en el gen p53 podrían considerarse como un estadio temprano de carcinoma anaplásico.

Introduction: A follicular adenoma of the thyroid gland is a kind of adenoma having bizarre nuclei with a histological worrisome appearance, though with a benign clinical evolution. Case: We present the case of a female patient with a past history of hyperthyroidism treated with tiamazol. A fine needle aspiration of the thyroid gland was performed; the cytology showed Hürthle's cells atypia, although, the specimen displayed features of follicular adenoma with bizarre nuclei. Up to now, there have not been reports of this entity in Ecuador. Discusion: Cells showing p53 mutations should be considered an early stage of anaplastic thyroid carcinoma.
Descritores: Tireoidectomia
Neoplasias da Glândula Tireoide
Adenoma
-Células Oxífilas
Hipertireoidismo
Metimazol
Limites: Humanos
Feminino
Pessoa de Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: EC162.1



página 1 de 79 ir para página                         
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde